<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1522">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825330</url>
  </required_header>
  <id_info>
    <org_study_id>NRX - US4</org_study_id>
    <nct_id>NCT01825330</nct_id>
  </id_info>
  <brief_title>Effect of NeuroAD on the Cognitive Function of Alzheimer Patients</brief_title>
  <official_title>Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuronix Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuronix Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The&#xD;
      NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NeuroAD system is a combined system of Transcranial Magnetic Stimulation and cognitive&#xD;
      training and is a non-invasive therapeutic system for the improvement of Alzheimer patients'&#xD;
      cognitive function.&#xD;
&#xD;
      A potential participant will undergo screening procedures to confirm eligibility to&#xD;
      participate in the study, followed by randomization procedure to one of the study groups -&#xD;
      treatment or sham (placebo) Patient will attend the clinic 5 times a week for 6 weeks,&#xD;
      approximately an hour every day for treatment/sham. The patient will be required to return to&#xD;
      the clinic for follow-up.&#xD;
&#xD;
      Up to 150 patients will be enrolled in up to 10 clinical sites in the US and Israel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from Baseline to week 7 in ADAS-Cog score. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline to week 7 in CGI-C score. CGI-C: Clinical Global Impression of Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to week 12 in ADAS-Cog score.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events, including Serious Adverse Events occurring at any time during the trial and follow-up.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>NeuroAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NeuroAD treatment, synchronized TMS and cognitive training stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS+Cog</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS and cognitive stimulation</intervention_name>
    <description>Synchronized TMS and cognitive stimulation to 6 brain areas.</description>
    <arm_group_label>NeuroAD</arm_group_label>
    <other_name>NeuroAD</other_name>
    <other_name>NICE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham</intervention_name>
    <arm_group_label>Sham TMS+Cog</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age 60-90 years&#xD;
&#xD;
          2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to&#xD;
             the DSM-IV criteria.&#xD;
&#xD;
          3. MMSE score 18 to 26&#xD;
&#xD;
          4. ADAS-Cog above 17&#xD;
&#xD;
          5. Physical clearance for study participation as evaluated by the clinician.&#xD;
&#xD;
          6. Spouse, family member or professional caregiver agree and capable of taking care and&#xD;
             be responsible for the participation of the patient in the study (answering questions&#xD;
             regarding the patient's condition and assuming responsibility for medication)&#xD;
&#xD;
          7. Agreement to participate in approximately 14 weeks during the study.&#xD;
&#xD;
          8. Normal to near-normal vision and hearing with correction as needed (e.g. corrective&#xD;
             lenses, hearing aid).&#xD;
&#xD;
          9. Fluent in English or Hebrew&#xD;
&#xD;
         10. Minimum of 8th grade education&#xD;
&#xD;
         11. If medicated for AD, then use of cholinesterase inhibitors, memantine or Ginko-biloba&#xD;
             for at least 3 months and on stable dose for at least 60 days prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CDR 0, 0.5 or 3&#xD;
&#xD;
          2. Severe agitation&#xD;
&#xD;
          3. Mental retardation&#xD;
&#xD;
          4. Patient lacking capacity to consent to study participation&#xD;
&#xD;
          5. Unstable medical condition&#xD;
&#xD;
          6. Use of benzodiazepines or barbiturates 2 weeks prior to screening&#xD;
&#xD;
          7. Pharmacological immunosuppression&#xD;
&#xD;
          8. Participation in a clinical trial with any investigational agent within 6 months prior&#xD;
             to study enrollment&#xD;
&#xD;
          9. History of Epileptic Seizures or Epilepsy&#xD;
&#xD;
         10. Contraindication for performing MRI scanning&#xD;
&#xD;
         11. Contraindication for receiving TMS treatment according to a TMS questionnaire&#xD;
&#xD;
         12. Pregnant women and women who have the ability to become pregnant unless they are on an&#xD;
             acceptable method of contraception during the study.&#xD;
&#xD;
         13. Patients with depression, bipolar disorder or psychotic disorders or any other&#xD;
             neurological or psychiatric condition (whether now or in the past), which the&#xD;
             Investigator finds as interfering with the study&#xD;
&#xD;
         14. Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more&#xD;
             than one year and or in remission less than 3 years) or severe sleep deprivation&#xD;
&#xD;
         15. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain&#xD;
             stimulators, aneurysm clips) with the exception of metal implants in mouth&#xD;
&#xD;
         16. Patients with personal history of either any clinically defined medical disorder&#xD;
             (which the investigator finds as interfering with the study) or any clinically defined&#xD;
             neurological/psychiatric disorder (other than AD), including (but not limited to):&#xD;
             epilepsy, stroke, brain lesions, substance abuse, vitamin B12 deficiency, abnormal&#xD;
             thyroid function, cerebrovascular condition, other neurodegenerative disease, head&#xD;
             trauma, multiple sclerosis; or personal history of previous neurosurgery or head&#xD;
             trauma that resulted in loss of consciousness.&#xD;
&#xD;
         17. Patients with any signs or symptoms of increased intracranial pressure, as determined&#xD;
             in a neurological exam.&#xD;
&#xD;
         18. Cardiac pacemakers&#xD;
&#xD;
         19. Implanted medication pumps&#xD;
&#xD;
         20. Intracardiac lines&#xD;
&#xD;
         21. Significant heart disease&#xD;
&#xD;
         22. Currently taking medication that lower the seizure threshold.&#xD;
&#xD;
         23. Patients on which TMS Motor Threshold cannot be found.&#xD;
&#xD;
         24. Patient underwent TMS treatment in the past.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlie Bernick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lou Ruvo Brain Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute Clinic</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Neurology and Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Brain Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Center for Brain Health Lakewood Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Beer Yaakov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.neuronixmedical.com/</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Alzheimer's</keyword>
  <keyword>TMS</keyword>
  <keyword>Cognitive Training</keyword>
  <keyword>NeuroAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

